Supernus Pharmaceuticals and Indivior target $125m in savings through CNS merger

Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. have agreed to combine in a tax-free, all-stock merger that would create a larger pharmaceutical company focused on central nervous system disorders, including addiction, psychiatry and neurological diseases. The combined business is expected to generate approximately $2.2 billion in annual net revenue and will market 11 medicines across several established and growing treatment categories.

The transaction would produce a company named Supernus, Inc., which would continue trading on the Nasdaq Global Market under the SUPN ticker. Supernus Pharmaceuticals President and Chief Executive Officer Jack Khattar is expected to lead the combined organization, while Indivior Pharmaceuticals director Tony Kingsley would become chair of its eight-member board. The companies are targeting completion during the fourth quarter of 2026, subject to shareholder, regulatory and other customary approvals.

Beyond its size, the Supernus Pharmaceuticals and Indivior merger represents an effort to build a more balanced neuroscience business around complementary commercial portfolios. Indivior Pharmaceuticals supplies the fast-growing addiction-treatment franchise led by Sublocade, while Supernus Pharmaceuticals contributes medicines for attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy and other neurological conditions.

Supernus Pharmaceuticals shareholders receive stock while Indivior investors get a $1bn dividend

Under the merger agreement, Supernus Pharmaceuticals stockholders would receive 1.5401 shares of Indivior Pharmaceuticals common stock for every Supernus Pharmaceuticals share they own. After closing, existing Indivior Pharmaceuticals stockholders are expected to own approximately 56.5% of the combined company, while Supernus Pharmaceuticals stockholders would hold about 43.5% on a fully diluted basis.

Indivior Pharmaceuticals stockholders would also receive a one-time special cash dividend totaling $1 billion immediately before the merger closes. The companies have secured a $650 million term-loan commitment from Citibank, N.A. to help finance that payment, with the remainder expected to come from cash held by the combined businesses.

That structure makes the transaction more complicated than a straightforward merger of equals. Indivior Pharmaceuticals investors are being offered a substantial cash distribution while retaining majority ownership of the new company. Supernus Pharmaceuticals investors, meanwhile, receive exposure to Indivior Pharmaceuticals’ addiction-treatment franchise and a potentially stronger cash-generating platform, but without an equivalent cash payment.

The fixed exchange ratio also means the economic value received by Supernus Pharmaceuticals shareholders can fluctuate with Indivior Pharmaceuticals’ stock price before closing. The companies themselves identified changes in their share prices, additional debt used to fund the dividend, regulatory approvals and the possibility of delayed or unrealized synergies among the transaction risks.

Sublocade growth gives the combined neuroscience portfolio a powerful commercial anchor

The central commercial asset behind the transaction is Sublocade, Indivior Pharmaceuticals’ monthly injectable buprenorphine treatment for opioid use disorder. Sublocade generated $253 million in second-quarter 2026 revenue, rising 21% from the corresponding period of 2025. United States revenue increased 22% to $238 million, supported by an 18% rise in dispensed unit volume and a record 32,816 new patient starts.

Indivior Pharmaceuticals reported total second-quarter revenue of $343 million, up 14%, while adjusted earnings before interest, taxes, depreciation and amortization more than doubled to $186 million. The company also raised its 2026 revenue guidance to between $1.295 billion and $1.365 billion and increased its Sublocade revenue forecast to between $1.01 billion and $1.05 billion.

Supernus Pharmaceuticals brings a broader portfolio that reduces dependence on a single disease market. Its second-quarter revenue increased 32% to $219.1 million, supported by Qelbree, Gocovri, Zurzuvae and Onapgo. Combined revenue from those four growth products rose 52% to $175.7 million.

Qelbree, a treatment for attention-deficit hyperactivity disorder, generated $89.2 million in quarterly sales, an increase of 15%. Onapgo, used to treat motor fluctuations in advanced Parkinson’s disease, produced $13.5 million, compared with $1.6 million a year earlier. Supernus Pharmaceuticals also recorded $35.4 million in collaboration revenue from Zurzuvae, reflecting its share of revenue reported by Biogen Inc. for the postpartum depression treatment.

The combination therefore brings together two different commercial engines. Indivior Pharmaceuticals offers a large, rapidly expanding product in Sublocade, while Supernus Pharmaceuticals supplies greater therapeutic diversification and several products with distinct growth trajectories. That balance could provide some protection if growth slows in an individual franchise, although Sublocade would still represent a substantial share of combined revenue.

Expected $125m in cost savings could expand cash flow and acquisition capacity

Supernus Pharmaceuticals and Indivior Pharmaceuticals expect the combined company to generate pro forma adjusted earnings before interest, taxes, depreciation and amortization of approximately $888 million. That projection includes at least $125 million in anticipated annual cost synergies. Management has not yet provided a detailed public breakdown of where all the savings would come from, but overlapping corporate, administrative and commercial functions are likely areas for integration.

The companies estimate pro forma net debt of approximately $878 million and a net leverage ratio below one times adjusted earnings before interest, taxes, depreciation and amortization. Those calculations include the $650 million expected borrowing for the special dividend but exclude transaction expenses, financing fees and the costs required to produce the projected synergies.

A sub-one-times leverage ratio would leave the combined company with flexibility to invest in its existing medicines, advance Supernus Pharmaceuticals’ internal pipeline and consider additional acquisitions. Supernus Pharmaceuticals is currently developing candidates including SPN-817 for treatment-resistant focal seizures, SPN-820 for major depressive disorder and SPN-443 for attention-deficit hyperactivity disorder.

The benefits will depend on management executing the integration without disrupting commercial momentum. Combining addiction medicine, psychiatric products and neurological franchises may produce scale, but it also creates a wider organization with different physician audiences, reimbursement environments and patient-support requirements. Cost reduction looks attractive on a presentation slide, yet cutting too deeply across specialized commercial teams could weaken the very growth franchises that justify the deal.

Supernus Pharmaceuticals stock jumps as investors weigh the merger economics

Investor sentiment was initially enthusiastic but became more selective as Monday’s session progressed. Supernus Pharmaceuticals shares traded at approximately $48.87 around midday on August 3, up about 9.5% from the previous close after reaching an intraday high of $57. Indivior Pharmaceuticals shares were around $39.51, down roughly 1.3%, after rising as high as $44.34 earlier in the session.

Both stocks had recorded stronger gains in premarket trading, with Supernus Pharmaceuticals rising more than 20% and Indivior Pharmaceuticals gaining nearly 10% shortly after the transaction was announced. The subsequent moderation suggests investors welcomed the strategic logic but were still assessing the ownership split, fixed exchange ratio, special dividend financing and integration risk. That interpretation is an inference from the changing market reaction rather than a confirmed explanation from either company.

Supernus Pharmaceuticals’ stronger relative performance indicates that its shareholders may be viewed as receiving the larger strategic transformation. The company would move from a mid-sized neuroscience portfolio to a platform with more than $2 billion in annual revenue, a leading opioid-use-disorder medicine and considerably greater cash-flow potential.

Indivior Pharmaceuticals investors face a different calculation. They would receive the $1 billion special dividend and majority ownership in the combined company, but they would also exchange a focused addiction-medicine investment for a broader pharmaceutical organization and assume part of the integration and financing risk.

The merger could create a credible CNS consolidator if management protects product momentum

In my assessment, the Supernus Pharmaceuticals and Indivior merger has stronger industrial logic than many pharmaceutical combinations built primarily around cost cutting. The companies operate in adjacent central nervous system markets, but their principal products do not substantially overlap. That gives the combined business an opportunity to reduce corporate duplication while preserving multiple distinct revenue franchises.

The transaction could also turn Supernus, Inc. into a more credible consolidator of neurological and psychiatric assets. With expected adjusted earnings before interest, taxes, depreciation and amortization approaching $900 million and leverage projected below one times, management may eventually have capacity to license or acquire additional commercial-stage medicines.

Execution remains the decisive factor. Investors should watch whether Sublocade maintains its current volume growth, whether Qelbree and Onapgo continue expanding, how quickly the companies identify the promised $125 million in savings and whether shareholder or regulatory reviews affect the planned fourth-quarter closing.

For patients and healthcare providers, the merger will matter most if the larger company can sustain investment across addiction medicine, Parkinson’s disease, attention-deficit hyperactivity disorder, depression and epilepsy. For shareholders, the test will be whether the transaction creates genuine revenue durability rather than simply producing a larger corporate structure with an impressive collection of products.

Key takeaways on what the Supernus Pharmaceuticals and Indivior Pharmaceuticals merger means

• Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock transaction that would create a central nervous system-focused drug company with approximately $2.2 billion in annual revenue.
• The combined company would market 11 medicines across addiction treatment, attention-deficit hyperactivity disorder, Parkinson’s disease, depression, epilepsy and other neurological conditions, giving it a broader and more diversified commercial portfolio.
• Indivior Pharmaceuticals stockholders are expected to receive a $1 billion special cash dividend before closing while retaining approximately 56.5% ownership of the combined company.
• Supernus Pharmaceuticals shareholders would own about 43.5% of the new business and gain exposure to Indivior Pharmaceuticals’ fast-growing Sublocade franchise for opioid use disorder.
• Sublocade generated $253 million in second-quarter 2026 revenue, making it the most important commercial asset supporting the merger’s strategic and financial rationale.
• Supernus Pharmaceuticals contributes additional growth products including Qelbree, Gocovri, Zurzuvae and Onapgo, reducing the combined company’s reliance on a single medicine or treatment market.
• Management expects at least $125 million in annual cost savings, which could strengthen cash flow and create greater capacity for pipeline investment, licensing deals and future acquisitions.
• The companies expect pro forma adjusted earnings before interest, taxes, depreciation and amortization of approximately $888 million, while projected leverage would remain below one times adjusted earnings.
• The market reaction was mixed, with Supernus Pharmaceuticals shares initially rising more strongly than Indivior Pharmaceuticals stock as investors assessed the merger structure, dividend financing and integration risks.
• The transaction’s success will depend on preserving Sublocade’s growth, expanding Supernus Pharmaceuticals’ newer products and achieving the promised cost savings without weakening specialized commercial operations.